Dear {{$doctorName}}
Subject: Assessment of
statin utilization and degree of lipid control in patients with
Type 2
Diabetes and hypertension with ASCVD or its risk factors
(BEAT-CVD - II Study)
Type 2 Diabetes is
strongly associated with atherogenic dyslipidemia which is very
common among south Asian population probably due to high consumption
of
carbohydrate foods. Hypertension occurs in more than 66% of patients
with type 2
diabetes, and retrospective analysis of a Framingham cohort, show
that it is the strongest
driver of cardiovascular outcomes in individuals with diabetes
ADA 2023
recommends for people with diabetes aged 40–75 at higher
cardiovascular
risk, including those with one or more atherosclerotic
cardiovascular disease risk factors,
it is recommended to use high intensity statin therapy to reduce LDL
cholesterol by <50% of baseline and to target an LDL cholesterol
goal of <70 mg/dL, and those with no ASCVD use
moderate-intensity statin therapy in addition to lifestyle
therapy. It is recommended to continue statin therapy in
diabetes patients over 75 years
At present, there is lack of country wide data to obtain
meaningful insights on guideline-
based drug utilization pattern of statins in patients with
diabetes mellitus and hypertension
with ASCVD and its risk factors.
This study is planned to evaluate drug utilization pattern
of antidiabetic drugs for
associated conditions on the backdrop of available published
clinical evidence on
improving the outcomes for comorbid conditions in obese or
overweight patients with
T2DM
We invite you to participate in this study. On acceptance,
you will need to capture the
relevant data as mentioned in the standard Data Collection
Form (DCF) provided, from
the patient’s medical records (case papers and
investigational reports – hereafter referred
as source documents).
We would recommend you to capture data fulfilling the
criteria as outlined in the protocol and whose relevant
laboratory investigations are available for the preceding 3
months.
We wish to inform you that the DCF will capture all data in
de-identified form and any
identifiable parameters which may potentially disclose the
identity of the patient such as
name or address will strictly not be captured so as to
ensure we maintain patient
confidentiality. We would encourage you to carefully fill
all available information to the
fullest as recommended in the DCF.
In alignment with good clinical research practices, an
independent Contract Research
Organization (CRO) will monitor this study and do the source
data verification of the data
captured in the DCF with copies of the patients’ source
medical records (case papers and
investigational reports) to ensure that the data entered in
the DCFs are accurate and in
alignment with the patients’ medical records. The study is
approved by independent
ethics committee.
If you agree to participate in the said study, we would
request you to sign and return the
enclosed reply along with your visiting card for accuracy of
records.
|
}}){kind=logo}